Literature DB >> 10858354

Evaluation of voriconazole pharmacodynamics using time-kill methodology.

M E Klepser1, D Malone, R E Lewis, E J Ernst, M A Pfaller.   

Abstract

Voriconazole is an investigational azole antifungal agent with activity against a variety of fungal species, including fluconazole-susceptible and -resistant Candida species and Cryptococcus neoformans. In this study, we employed in vitro time-kill methods to characterize the relationship between concentrations of voriconazole and its fungistatic activity against Candida albicans, Candida glabrata, Candida tropicalis, and C. neoformans. Isolates were exposed to voriconazole concentrations ranging from 0.0625 to 16 times the MIC, and the viable colony counts were determined over time. The 50 and 90% effective concentrations (EC(50) and EC(90), respectively) were determined at 8, 12, and 24 h following the addition of voriconazole. At each time point, near-maximal fungistatic activity, as indicated by the EC(90), was noted at a drug concentration of approximately three times the MIC. Additionally, EC(50) and EC(90) did not change over time, thus suggesting that the rate of activity was not improved by increasing concentrations. Voriconazole exhibits non-concentration-dependent pharmacodynamic characteristics in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858354      PMCID: PMC89985          DOI: 10.1128/AAC.44.7.1917-1920.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species.

Authors:  P Belanger; C C Nast; R Fratti; H Sanati; M Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

3.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

Authors:  M E Klepser; E J Wolfe; R N Jones; C H Nightingale; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods.

Authors:  M E Klepser; E J Ernst; R E Lewis; M E Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

Authors:  A Louie; G L Drusano; P Banerjee; Q F Liu; W Liu; P Kaw; M Shayegani; H Taber; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  In vitro activity of voriconazole against Candida species.

Authors:  C A Kauffman; L T Zarins
Journal:  Diagn Microbiol Infect Dis       Date:  1998-05       Impact factor: 2.803

7.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.

Authors:  M E Klepser; E J Wolfe; M A Pfaller
Journal:  J Antimicrob Chemother       Date:  1998-03       Impact factor: 5.790

8.  Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.

Authors:  D Andes; M van Ogtrop
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

9.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

10.  Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing.

Authors:  M D Witt; R J Lewis; R A Larsen; E N Milefchik; M A Leal; R H Haubrich; J A Richie; J E Edwards; M A Ghannoum
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

View more
  27 in total

1.  In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Shana M Gunderson; Robert A Hayes; John P Quinn; Larry H Danziger
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 3.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

4.  In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect.

Authors:  S M Gunderson; H Hoffman; E J Ernst; M A Pfaller; M E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Supradescemetic voriconazole injection for Candida parapsilosis keratitis.

Authors:  Nikolaos Mamas; Konstantinos Andreanos; Klio Chatzistefanou; Petros Petrou; Dimitrios Brouzas; George Kymionis; Chrysanthi Koutsandrea; Konstantinos Droutsas
Journal:  Int Ophthalmol       Date:  2017-04-18       Impact factor: 2.031

6.  Amphiphilic Tobramycin Analogues as Antibacterial and Antifungal Agents.

Authors:  Sanjib K Shrestha; Marina Y Fosso; Keith D Green; Sylvie Garneau-Tsodikova
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

Review 7.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

Review 9.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

10.  Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie VanHecker; Daniel Diekema; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.